Literature DB >> 34168217

Association of hepatic steatosis derived from ultrasound and quantitative MRI with prediabetes in the general population.

Till Ittermann1, Henry Völzke1,2,3, Muhammad Naeem4,5, Robin Bülow6,2, Sabine Schipf1, Nicole Werner1, Marcus Dörr7,2, Markus M Lerch8, Jens-Peter Kühn9, Wolfgang Rathmann3,10, Matthias Nauck11, Marcello Ricardo Paulista Markus7,2.   

Abstract

The aim of our study was to investigate the association of hepatic steatosis derived from quantitative ultrasound and magnetic resonance imaging (MRI) with prediabetes in a large population-based study conducted in Northeast Germany. Hepatic steatosis was assessed through transabdominal ultrasound and quantitative MRI. For analysis we included 1622 subjects with MRI who participated in an oral glucose tolerance test and reported no known type 2 diabetes mellitus (T2DM). We classified participants as proposed by the American Diabetes Association: isolated impaired fasting glucose (i-IFG), isolated impaired glucose tolerance (i-IGT), combined IFG and IGT (IFG + IGT), and undiagnosed T2DM. Regression models were adjusted for age, sex body mass index and alcohol consumption. We observed positive associations of hepatic steatosis with glycated hemoglobin, fasting glucose and insulin, 2-h glucose and insulin, as well as homeostasis model assessment-insulin resistance index. Similarly, individuals having hepatic steatosis as defined by MRI had a higher relative risk ratio (RR) to be in the prediabetes groups i-IFG (RR = 1.6; 95% confidence interval (CI) 1.2; 2.2), i-IGT (RR = 3.3, 95% CI 2.0; 5.6) and IFG + IGT (RR = 2.5, 95% CI 1.6; 3.9) or to have undiagnosed T2DM (RR = 4.8, 95% CI 2.6; 9.0). All associations were attenuated when defining hepatic steatosis by ultrasound. Hepatic steatosis is associated with prediabetes and undiagnosed T2DM in the general population. Quantitative liver MRI revealed stronger associations with prediabetes and undiagnosed T2DM compared to ultrasound, which indicates the higher sensitivity and specificity of MRI to determine hepatic steatosis.

Entities:  

Year:  2021        PMID: 34168217     DOI: 10.1038/s41598-021-92681-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  41 in total

Review 1.  A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Authors:  Amedeo Lonardo; Simonetta Lugari; Stefano Ballestri; Fabio Nascimbeni; Enrica Baldelli; Mauro Maurantonio
Journal:  Acta Diabetol       Date:  2018-12-05       Impact factor: 4.280

2.  Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Ravi V Shah; Matthew A Allison; João A C Lima; David A Bluemke; Siddique A Abbasi; Pamela Ouyang; Michael Jerosch-Herold; Jingzhong Ding; Matthew J Budoff; Venkatesh L Murthy
Journal:  Atherosclerosis       Date:  2015-07-15       Impact factor: 5.162

Review 3.  Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.

Authors:  Amedeo Lonardo; Stefano Ballestri; Giulio Marchesini; Paul Angulo; Paola Loria
Journal:  Dig Liver Dis       Date:  2014-11-18       Impact factor: 4.088

4.  Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease.

Authors:  Jayani Manchanayake; Shivakumar Chitturi; Christopher Nolan; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2011-03       Impact factor: 4.029

Review 5.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Authors:  Fernando Bril; Kenneth Cusi
Journal:  Diabetes Care       Date:  2017-03       Impact factor: 19.112

6.  Bi-directional analysis between fatty liver and cardiovascular disease risk factors.

Authors:  Jiantao Ma; Shih-Jen Hwang; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Raymond T Chung; Emelia J Benjamin; Daniel Levy; Caroline S Fox; Michelle T Long
Journal:  J Hepatol       Date:  2016-10-10       Impact factor: 25.083

Review 7.  Non-alcoholic fatty liver disease and diabetes.

Authors:  Jonathan M Hazlehurst; Conor Woods; Thomas Marjot; Jeremy F Cobbold; Jeremy W Tomlinson
Journal:  Metabolism       Date:  2016-01-11       Impact factor: 8.694

8.  Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults.

Authors:  Sean Chun-Chang Chen; Shan Pou Tsai; Jing-Yun Jhao; Wun-Kai Jiang; Chwen Keng Tsao; Ly-Yun Chang
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

9.  Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study.

Authors:  Yaru Li; Jing Wang; Yuhan Tang; Xu Han; Bing Liu; Hua Hu; Xiulou Li; Kun Yang; Jing Yuan; Xiaoping Miao; Ping Yao; Sheng Wei; Youjie Wang; Yuan Liang; Xiaomin Zhang; Huan Guo; An Pan; Handong Yang; Frank B Hu; Tangchun Wu; Meian He
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

Review 10.  Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.

Authors:  David Højland Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Cell Mol Life Sci       Date:  2018-06-23       Impact factor: 9.261

View more
  1 in total

Review 1.  SHIP-MR and Radiology: 12 Years of Whole-Body Magnetic Resonance Imaging in a Single Center.

Authors:  Norbert Hosten; Robin Bülow; Henry Völzke; Martin Domin; Carsten Oliver Schmidt; Alexander Teumer; Till Ittermann; Matthias Nauck; Stephan Felix; Marcus Dörr; Marcello Ricardo Paulista Markus; Uwe Völker; Amro Daboul; Christian Schwahn; Birte Holtfreter; Torsten Mundt; Karl-Friedrich Krey; Stefan Kindler; Maria Mksoud; Stefanie Samietz; Reiner Biffar; Wolfgang Hoffmann; Thomas Kocher; Jean-Francois Chenot; Andreas Stahl; Frank Tost; Nele Friedrich; Stephanie Zylla; Anke Hannemann; Martin Lotze; Jens-Peter Kühn; Katrin Hegenscheid; Christian Rosenberg; Georgi Wassilew; Stefan Frenzel; Katharina Wittfeld; Hans J Grabe; Marie-Luise Kromrey
Journal:  Healthcare (Basel)       Date:  2021-12-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.